{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:25:37Z","timestamp":1788013537354,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Systemic chemotherapy or chemoradiotherapy is the initial primary option for patients with locally advanced pancreatic cancer (LAPC). This study analyzed the effect of FOLFIRINOX and assessed the factors influencing conversion to surgical resectability for LAPC.<\/jats:p>\n            <jats:p>Sixty-four patients with LAPC who received FOLFIRINOX as initial chemotherapy were enrolled retrospectively. Demographic characteristics, tumor status, interval\/dosage\/cumulative relative dose intensity (cRDI) of FOLFIRINOX, conversion to resection, and clinical outcomes were reviewed and factors associated with conversion to resectability after FOLFIRINOX were analyzed.<\/jats:p>\n            <jats:p>After administration of FOLFIRINOX (median 9 cycles, 70% of cRDI), the median patient overall survival (OS) was 17.0 months. Fifteen of 64 patients underwent surgery and R0 resection was achieved in 11 patients. During a median follow-up time of 9.4 months after resection, cumulative recurrence rate was 28.5% at 18 months after resection. The estimated median OS was significantly longer for the resected group (&gt;40 months vs 13 months). There were no statistical differences between the resected and non-resected groups in terms of baseline characteristics, tumor status and hematologic adverse effects. The patients who received standard dose of FOLFIRINOX had higher probability of subsequent resection compared with patients who received reduced dose, although cRDIs did not differ between groups.<\/jats:p>\n            <jats:p>FOLFIRINOX is an active regimen in patients with LAPC, given acceptable resection rates and promising R0 resection rates. Additionally, our data demonstrate it is advantageous for obtaining resectability to administer FOLFIRINOX without dose reduction.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000013592","type":"journal-article","created":{"date-parts":[[2018,12,15]],"date-time":"2018-12-15T02:51:23Z","timestamp":1544842283000},"page":"e13592","source":"Crossref","is-referenced-by-count":28,"title":["Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer"],"prefix":"10.1097","volume":"97","author":[{"given":"Jongchan","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Seoul National University, College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong-chan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University, College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Gromski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, Indiana University School of Medicine, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoung Woo","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chungbuk National University, College of Medicine, Chungbuk National University Hospital, Cheongju, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinwon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University, College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaihwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University, College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hyeok","family":"Hwang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University, College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0002-9610(05)80406-4","article-title":"Prognostic indicators for survival after resection of pancreatic adenocarcinoma","volume":"165","author":"Geer","year":"1993","journal-title":"Am J Surg"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/nrclinonc.2009.236","article-title":"Advanced pancreatic carcinoma: current treatment and future challenges","volume":"7","author":"Stathis","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2012-0435","article-title":"FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts general hospital cancer center experience","volume":"18","author":"Jason","year":"2013","journal-title":"Oncologist"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/SLA.0000000000000867","article-title":"Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer","volume":"261","author":"Cristina R","year":"2015","journal-title":"Ann Surg"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.soc.2009.11.006","article-title":"Management of borderline resectable pancreatic cancer","volume":"19","author":"Alysadra","year":"2010","journal-title":"Surg Oncol Clin N Am"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/MPA.0000000000000314","article-title":"FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies","volume":"44","author":"Petrelli","year":"2015","journal-title":"Pancreas"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1471-2407-12-199","article-title":"A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma","volume":"12","author":"Hosein","year":"2012","journal-title":"BMC Cancer"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S1470-2045(16)00172-8","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"17","author":"Mustafa","year":"2016","journal-title":"Lancet Oncol"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1245\/s10434-011-2110-8","article-title":"Neoadjuvant\/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies","volume":"19","author":"Andriulli","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.pan.2015.08.010","article-title":"Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma","volume":"15","author":"Moh\u2019d","year":"2015","journal-title":"Pancreatology"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2017.02.010","article-title":"Optimal dose reduction of FOLFIRINOX for preserving tumour response in advanced pancreatic cancer: using cumulative relative dose intensity","volume":"76","author":"Jong-chan","year":"2017","journal-title":"Eur J Cancer"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/cas.12501","article-title":"Phase II study of FOLFIRINOX for chemotherapy-na\u00efve Japanese patients with metastatic pancreatic cancer","volume":"105","author":"Takuji","year":"2014","journal-title":"Cancer Sci"},{"key":"R16-20230914","first-page":"1","article-title":"Primary systemic therapy in resectable pancreatic ductal adenocarcinoma using mFOLFIRINOX: A pilot study","author":"de","year":"2017","journal-title":"J Surg Oncol"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.radonc.2014.10.015","article-title":"Brunner, Ursula Nestle, Anca-Ligia Grosu et al. SBRT in pancreatic cancer: what is the therapeutic window?","volume":"114","author":"Thomas","year":"2015","journal-title":"Radiother Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201812140-00068","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T20:57:23Z","timestamp":1694725043000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201812140-00068"}},"subtitle":["A single center experience"],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":16,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000013592","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12]]}}}